DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
- Written by PR Newswire Asia - Asian Spectator
CAMBRIDGE, England and SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus vaccine trial, to announce its new portfolio of pre-pandemic Bird-Flu, supra-Seasonal and...
